Evidence mapPaperPMID 41521235Full record

ArticleScientific reports2026

Shen-Shuai-II-Recipe inhibits aerobic glycolysis through SIRT1 in 5/6 ablation/infarction renal failure model.

Tianying Lan, Xinyue Zhang, Xiao Lyu, Ming Wu, Chen Wang, Liuyi Yang

Abstract read
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Tianying Lan *Nephrology, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Xinyue Zhang *Nephrology, Shanghai Seventh People's Hospital, Shanghai, China.
Xiao LyuNephrology, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Ming WuNephrology, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Chen WangNephrology, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China. chenwang42@163.com.
Liuyi YangNephrology, Shanghai Baoshan Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai, China. liuyiyang328@163.com.

Funding

National Natural Science Foundation of China 81973770Youth Fund of the National Natural Science Foundation of China 82205018
6 · The paper itself

Abstract

Renal fibrosis is the common pathological feature of chronic kidney diseases, which is in parallel with increasing energy demand in proximal tubular epithelial cells during the metabolic shift from fatty acid oxidation to glycolysis. Shen-Shuai-II-Recipe (SSR) is a traditional Chinese medicine formula with known renal benefits in patients with chronic kidney disease (CKD) and has been shown to intervene in renal energy metabolism in a rodent model of CKD. We aimed to explore the mechanism underlying the protective effect of SSR against CKD. A 5/6 ablation/infarction (A/I) renal failure model was established in rats, followed by 8 weeks of gavage feeding with SSR or Losartan, a positive control. For in vitro experiments, normal rat kidney-52E (NRK-52E) cells were cultured under hypoxic condition (1% O

Indexed as

Drugs, Chinese HerbalGlycolysisRenal Insufficiency, ChronicSirtuin 1AnimalsCell LineDisease Models, AnimalFibrosisHypoxia-Inducible Factor 1, alpha SubunitKidneyMaleRatsDrugs, Chinese HerbalHypoxia-Inducible Factor 1, alpha SubunitSirt1 protein, ratSirtuin 1Aerobic glycolysisCKDRenal fibrosisSIRT1

Identifiers

PMID41521235
PMCPMC12877090

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.